-
Phase 3 Trial Shows Promising Results for Encorafenib Combination Regimen for Patients with Metastatic Colorectal Cancer
05 Feb 2025 22:57 GMT
… and Company) and mFOLFOX6 (fluorouracil, leucovorin, and oxaliplatin) demonstrated … and mFOLFOX6 was granted FDA accelerated approval for … deputy chair of Gastrointestinal Medical Oncology at The … the phase 3 trial, serious treatment adverse events occurred …
-
Pfizer’s BRAFTOVI Combo Boosts Survival in Phase 3 BREAKWATER Trial
05 Feb 2025 02:35 GMT
… ERBITUX ) and mFOLFOX6 (fluorouracil, leucovorin and oxaliplatin) in … V600E mutation. The trial showed a statistically significant … and Drug Administration (FDA) in December 2024 for treatment-naïve … simultaneously published in Nature Medicine in January 2025. …
-
Topical Drug Delivery May Offer Welcome Alternatives for Breast Cancer Treatment
05 Feb 2025 00:06 GMT
… included trials that examined the possibility of alternative drug … nanoparticles. Breast cancer medications studied included 5-fluorouracil, α-santalol, celecoxib … treatment. The underlying takeaway is that topical, targeted drug delivery increases drug …
-
Updated BREAKWATER Trial Data Show Significant Survival Improvement with Braftovi Combination in Metastatic Colorectal Cancer
03 Feb 2025 15:40 GMT
… (cetuximab) and mFOLFOX6 (fluorouracil, leucovorin, and oxaliplatin) … label, multicenter BREAKWATER trial is evaluating Braftovi … profile for each medication and no new … FDA-Approves-Pfizer%E2%80%99s-BRAFTOVI%C2%AE-Combination-Regimen-as-First-Line-Treatment …
-
Pfizer Trial For Colorectal Cancer Treatment Shows Improved Survival In Late-Stage Study
03 Feb 2025 16:25 GMT
… as Erbitux) and mFOLFOX6 (fluorouracil, leucovorin and oxaliplatin) for … secondary endpoint in the trial.
The FDA granted accelerated approval … in December 2024 for treatment-naïve patients with BRAF … presentation at an upcoming medical meeting.
Last week, …
-
Braftovi Plus Erbitux With mFOLFOX6 May Improve Responses in BRAF V600E+ mCRC
08 Feb 2025 17:11 GMT
… treatment with the combination of Braftovi (encorafenib), Erbitux (cetuximab), and mFOLFOX6 (fluorouracil … phase 3 BREAKWATER trial presented at the … (GI) Medical Oncology, Division of Cancer Medicine; leader of … as detected by an FDA-approved test.
BREAKWATER …
-
The Combination of D-TACE-HAIC, Lenvatinib, and PD-1 Inhibitors Shows Significant Clinical Efficacy in Patients with Unresectable Hepatocellular Carcinoma
06 Feb 2025 17:10 GMT
… Biliary Surgery, the First Medical Center of PLA General … : unresectable hepatocellular carcinomas, drug-eluting beads-transarterial chemoembolization … fluorouracil (2400 mg/m2) for 46 h.
Group B treatment … FOXAI: a Phase II trial evaluating the efficacy and …
-
Comparison of efficacy and toxicity of chemotherapeutic regimens used as adjuvant and/or neoadjuvant chemotherapy in penile cancer patients.
05 Feb 2025 11:10 GMT
… received various chemotherapy regimens: 5-Fluorouracil with Cisplatin (FP), Paclitaxel with … Kumar Gupta
National Institute of Pharmaceutical Education and Research (NIPER), Hajipur …
-
Dual-Targeted Therapies Plus Chemo Improve Objective Response Rate in BRAF V600E Metastatic CRC
05 Feb 2025 10:04 GMT
… (modified folinic acid [or levofolinate], fluorouracil, and oxaliplatin regimen [mFOLFOX6]) is … online Jan. 25 in Nature Medicine. The research was published to … was also received from other pharmaceutical companies.
Abstract/Full Text …
-
Encorafenib Combo Improves PFS in Metastatic Colorectal Cancer
05 Feb 2025 01:03 GMT
… Erbitux) and chemotherapy consisting of fluorouracil, leucovorin, and oxaliplatin ( … the FDA.2 Additional results from the trial focused … presented at an upcoming medical meeting.
“We are … received prior treatment were enrolled in the trial.4 Additional …
About
© 1995-2025